Key result
Targeting the central AT1 receptor may be a potential treatment approach for overactive bladder by inhibiting central Angiotensin II-induced facilitation of the micturition reflex.
Why the study?
Current treatments for overactive bladder are limited by lack of response or discontinuation due to adverse events, warranting exploration of central targets like the brain angiotensin II type 1 receptor.
Does targeting the central AT1 receptor improve symptoms in patients with overactive bladder?
Does targeting the central AT1 receptor improve symptoms in patients with overactive bladder?
Targeting the central AT1 receptor with blockers like telmisartan may represent a novel therapeutic approach for overactive bladder.
Does not support telmisartan for overactive bladder; leaves open central AT1 receptor as a hypothesis-generating target.
-adrenoceptor agonists, and botulinum toxin are currently being used for treatment. However, several patients do not respond to these medications or discontinue them because of adverse events. Angiotensin II (Ang II) is a neuropeptide produced in both brain and peripheral tissues, and Ang II type 1 (AT1) receptors, which are important regions for the micturition reflex, are widely expressed in the cerebral cortex, paraventricular nucleus, solitary tract nucleus, and periaqueductal gray. Our data showed that cumulative central Ang II administration, even at low doses, shortened the intercontraction interval without affecting the blood pressure or blood catecholamine levels. Additionally, Ang II can enhance the micturition reflex by suppressing the GABAergic nervous system and stimulating the downstream pathway of the AT1 receptor. The peripherally administered AT1 receptor blocker telmisartan inhibited central Ang II-induced facilitation of the micturition reflex. Targeting the central AT1 receptor may be a potential treatment approach for patients with overactive bladder. This review introduces the brain AT1 receptor as a therapeutic target in overactive bladder.
No takes yet. Share an insight, caveat, or question.
Shogo Shimizu (2023) conducted a review in Overactive bladder. Targeting the central AT1 receptor was evaluated. Targeting the central AT1 receptor may be a potential treatment approach for overactive bladder by inhibiting central Angiotensin II-induced facilitation of the micturition reflex.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: